ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · J Infect Dis · 2026-09-23

Secondary analysis of three phase 3 switch trials (1227 virologically suppressed adults with HIV-1): HIV-1 RNA <50 copies/mL at week 48 on doravirine/islatravir was ≥88% with or without baseline proviral NNRTI RAMs (26.3%) or M184I/V (5.7%).

Secondary analysisn = 1,227
Diamond et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA
Infectious diseases · Clin Infect Dis · 2026-09-02

Phase 3 double-blind trial of monthly oral islatravir vs daily FTC/tenofovir PrEP in 494 cisgender men and transgender women: adverse events 64.3% vs 77.1%, mostly mild; lymphocytes fell 7.4% by month 3 on islatravir, which was stopped early; efficacy not assessed.

RCTn = 494
Landovitz et al. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study
Infectious diseases · Lancet · 2026-08-12

In 626 virologically suppressed adults with HIV-1, switching to once-weekly oral islatravir-lenacapavir was non-inferior to continuing daily standard of care: HIV-1 RNA ≥50 copies/mL at week 48 in 0·3% vs 1·3%. Treatment-related adverse events 18% vs <1%.

RCTn = 634
Colson et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Infectious diseases · Lancet HIV · 2026-02-25

Phase 3 non-inferiority RCT in 536 treatment-naive adults with HIV-1: doravirine-islatravir was non-inferior to bictegravir-emtricitabine-tenofovir alafenamide for HIV-1 RNA <50 copies/mL at week 48 (91.8% vs 90.6%); doravirine resistance arose in 2 participants.

RCTn = 536
Rockstroh et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Infectious diseases · Lancet · 2026-02-07

In 513 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing bictegravir/emtricitabine/tenofovir alafenamide at week 48 (viral load ≥50 copies/mL 1.5% vs 0.6%).

RCTn = 514
Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Infectious diseases · Lancet · 2026-02-07

In 551 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing baseline oral ART at week 48 (viral load ≥50 copies/mL 1.4% vs 4.9%); treatment-related adverse events were commoner (12.0% vs 4.9%).

RCTn = 553
Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.